EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement

Raymond J So iD, Julio C Hidalgo Lopez, Samir A Ballestas, Adam M Klein, Conor Steuer, Dong M Shin, Marin Abousaud, Yong Teng, Nabil F Saba, Andrew T Tkaczuk, Eric S Schaefer, Tanguy Y Seiwert und 2 weitere

The Laryngoscope · 2024

DOI: 10.1002/lary.30893 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2024. Verfasst von Raymond J So und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Papillomavirus Infections, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pulmonary papillomatosis is a rare but severe manifestation of recurrent respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for pulmonary RRP are limited. This study's objective was to characterize disease response of pulmonary RRP to systemic bevacizumab.

Methods

A retrospective review was performed to identify patients with pulmonary RRP seen at three medical institutions. Clinical symptoms, CT findings, and disease response were compared before and after initiation of systemic bevacizumab therapy. Disease response was categorized as complete response, partial response, stabilization, or progression for each subsite involved by papilloma.

Results

Of the 12 pulmonary RRP patients treated with systemic bevacizumab, 4 (33.3%) were male, and 11 (91.7%) were juvenile‐onset RRP patients. All presented with laryngeal, tracheal, and pulmonary RRP. The median (range) age at first bevacizumab infusion was 48.1 (19.5–70.2) years. Progression to pulmonary malignancy was identified in 3 (25.0%) patients, 2 before initiation of and 1 after complete cessation of bevacizumab therapy. Clinical symptoms such as dyspnea (75.0% vs. 25.0%; p = 0.01) and dysphagia and/or odynophagia (33.3 vs. 0.0%; p = 0.03) were significantly decreased following bevacizumab therapy. Compared with pre‐treatment baseline, 9 (75.0%) patients experienced a stable‐to‐partial response in the lungs to systemic bevacizumab, and 10 (83.3%) experienced partial‐to‐complete responses in the larynx and trachea.

Conclusion

Systemic bevacizumab is effective in stabilizing progression in even the most severe cases of RRP, with both a dramatic reduction in laryngeal and tracheal disease as well as a stable‐to‐partial response of pulmonary involvement in a majority of patients. Level of Evidence 4 Laryngoscope , 134:577–581, 2024

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Tract InfectionsPapillomavirus InfectionsLung NeoplasmsHumansMaleMiddle AgedAgedFemaleBevacizumabPathologic Complete Response

Stichwörter der Autor:innen

pulmonaryrecurrent respiratory papillomatosissystemic bevacizumab

Substanzen

Bevacizumab

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
  • Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, Georgia, U.S.A.
  • Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, U.S.A.
  • Department of Pharmaceutical Sciences, Emory University, Atlanta, Georgia, U.S.A.
  • Highlands Oncology, Fayetteville, Arkansas, U.S.A.
  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

ORCID-Profile: Raymond J So

Zitieren

APA

So, R. J., Hidalgo Lopez, J. C., Ballestas, S. A., Klein, A. M., Steuer, C., Shin, D. M., Abousaud, M., Teng, Y., Saba, N. F., Tkaczuk, A. T., Schaefer, E. S., Seiwert, T. Y., McClellan, K., & Best, S. R. (2024). Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement. The Laryngoscope. https://doi.org/10.1002/lary.30893

Vancouver

So RJ, Hidalgo Lopez JC, Ballestas SA, Klein AM, Steuer C, Shin DM, et al. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement. The Laryngoscope. 2024. doi:10.1002/lary.30893

BibTeX
@article{So2024,
  author = {So, Raymond J and Hidalgo Lopez, Julio C and Ballestas, Samir A and Klein, Adam M and Steuer, Conor and Shin, Dong M and Abousaud, Marin and Teng, Yong and Saba, Nabil F and Tkaczuk, Andrew T and Schaefer, Eric S and Seiwert, Tanguy Y and McClellan, Kim and Best, Simon R},
  title = {Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement},
  journal = {The Laryngoscope},
  year = {2024},
  doi = {10.1002/lary.30893}
}
Kostenlos starten →